Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today report ...

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials [3] Event Announcement - AIM ImmunoTech will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, which will be held virtually from August 19-21, 2025 [1] - The presentation is scheduled for August 20, 2025, at 2:40 PM ET, and will be led by Thomas Equels, the Chief Executive Officer, President & Executive Vice Chairman of the company [1]

Core Insights - AIM ImmunoTech Inc. presented its drug Ampligen at the U.S.-Poland Science and Technology Symposium 2025, highlighting its potential in immunotherapy [1][2] - Dr. Pawel Kalinski emphasized the importance of public-private partnerships in advancing cancer research and treatment development [2][4] - The conference focused on "Opportunities in Singularity," showcasing collaboration between various institutions and organizations [3] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [5] - Ampligen, the company's lead product, is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist with broad-spectrum activity in clinical trials [5] Future Initiatives - The CEO of AIM stated the goal of establishing clinical partnerships and licensing agreements in Europe, particularly in Poland, to enhance cancer research [4]

Core Viewpoint - AIM ImmunoTech Inc. has received a warning from NYSE American regarding non-compliance with minimum stockholders' equity requirements, with a deadline to regain compliance by June 11, 2026 [2][3]. Group 1: Compliance Issues - As of March 31, 2025, AIM reported a stockholders' deficit of negative $3.9 million, failing to meet the required equity of $4.0 million due to losses in three of the last four fiscal years [2][3]. - The NYSE American had previously issued a warning on December 17, 2024, and the current notification indicates that the deficiency remains unresolved [3]. - AIM has submitted a plan to regain compliance, which has been accepted by NYSE American, allowing until June 11, 2026, to rectify the situation [3]. Group 2: Trading Status - AIM's common stock resumed trading on NYSE American under the symbol "AIM" on June 17, 2025, and the warning does not affect trading or the company's business operations [4]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod) [5].

Core Viewpoint - AIM ImmunoTech Inc. has announced the withdrawal of its delisting determination by NYSE Regulation, allowing its common stock to resume trading on the NYSE American starting June 17, 2025 [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad-spectrum activity in clinical trials [2]

Core Insights - AIM ImmunoTech Inc. presented clinical trial data for its drug Ampligen at the Annual Meeting of the American Association of Immunologists, highlighting its potential in treating cancers and immune disorders [1][2]. Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. Its lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a highly selective TLR3 agonist [3]. Clinical Data Presentation - The presentation by Dr. Pawel Kalinski discussed the unique selectivity of Ampligen in promoting CTL (cytotoxic T lymphocyte) influx into the tumor microenvironment (TME) while avoiding Treg (regulatory T cell) attraction. This selectivity differentiates Ampligen from other treatments like poly-I:C [2]. - Mechanistic data indicated that Ampligen's selectivity is due to its avoidance of helicase-dependent activation of NFkB, which prevents the induction of undesirable inflammatory factors while focusing on tumor tissues [2]. CEO Commentary - The CEO of AIM ImmunoTech expressed confidence in Ampligen's potential as a therapeutic option for unmet medical needs, particularly in the context of deadly cancers [3].